Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis  

作　　者：Abigail Medford Jonathan Childs Ashleigh Little Sanjukta Chakraborty Leonardo Baiocchi Gianfranco Alpini Shannon Glaser 

机构地区：[1]Department of Medical Physiology,Texas A&M University School of Medicine,Bryan,TX,USA [2]Hepatology Unit,University of Tor Vergata,Rome,Italy [3]Division of Gastroenterology and Hepatology,Department of Medicine,Indiana University School of Medicine,Indianapolis,IN,USA

出　　处：《Journal of Clinical and Translational Hepatology》2023年第4期949-957,共9页临床与转化肝病杂志（英文版）

基　　金：This work was supported by Texas A&M University,College of Medicine,Department of Medical Physiology,Bryan,TX,the NIH grants DK110035,DK129236,and AA028711 to Drs.Alpini,and Glaser,Cancer Prevention&Research Institute of Texas(CPRIT)-RP210213 to Dr.Chakraborty;the Hickam Endowed Chair,Gastroenterology,Medicine,Indiana University,the Indiana University Health-Indiana University School of Medicine Strategic Research Initiative,the Senior Career Scientist Award(IK6 BX004601);the VA Merit award(5I01BX000574)to GA from the United States Department of Veteran’s Affairs,Biomedical Laboratory Research and Development Service.The views expressed in this article are those of the authors and do not necessarily represent the Department of Veterans Affairs views.

摘　　要：The liver has a vital role in many metabolic and regulatory processes in the body.Primary biliary cholangitis(PBC),previously known as primary biliary cirrhosis,is a chronic cholestatic autoimmune disease of the intrahepatic bile ducts associated with loss of tolerance to mitochondrial antigens.At this time there is no definitive cure for PBC;however,ursodeoxycholic acid(UDCA)has been shown to reduce injury when administered as the first line of treatment.Additional therapeutics can be given concurrently or as an alternative to UDCA to manage the symptoms and further curb disease progression.Currently,a liver transplant is the only potentially curative option when the patient has developed end-stage liver disease or intractable pruritus.This review aims to delineate the pathogenesis of primary biliary cholangitis and shed light on current therapeutic strategies in the treatment of PBC.

关 键 词：Cholestatic liver disease Therapeutic approaches Biliary epithelia ursodeoxycholic acid 

分 类 号：R575[医药卫生—消化系统]